Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q3 2025 · 10-Q
Revenue$12.81M$12.81M−5.4% vs Q3 2024 Net Income-$15.45M-$15.45MN/M vs Q3 2024 EPS Diluted-$0.14-$0.14N/M vs Q3 2024 Operating Income-$11,479,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$12,884,000N/M Margins · derivedOperating margin-89.6%−28.4 pt vs Q3 2024
Net margin-120.6%−35.6 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 5, 2025 · 36 d after period end